ASH News Daily 2013 - Day 2 - (Page A-11)

1.5" BECAUSE THE CONSEQUENCES CAN BE DEVASTATING1-4 aHUS 70% of aHUS* patients (with the most common mutation ) die, require dialysis, of aHUS* patients (with the most common mutation†) die, require dialysis, or have permanent renal damage within 1 year or have permanent renal damage within 1 year4 * In aHUS, uncontrolled complement activation leads to systemic thrombotic microangiopathy (TMA)4,12-16 * 33% to 40% of all patients die or progress to end-stage renal disease with the fi rst clinical manifestation4,12 * Plasma exchange/infusion (PE/PI) does not address chronic, uncontrolled complement activation, the underlying cause of TMA in aHUS12,16-22 - There have been no well-controlled trials showing PE/PI to be either safe or effective in the treatment of aHUS23 * Differential diagnosis of aHUS is warranted3,10 *aHUS = atypical hemolytic uremic syndrome. †CFH mutations = most common population. Visit Alexion booth #3521 at ASH, December 7-10, 2013, Ernest N. Morial Convention Center, New Orleans, LA, for more information. For more information about PNH and aHUS, visit www.PNHSource.com and www.aHUSSource.com F:10.75" Y75 Y50 Y25 R100 R75 R50 R25 G100 G75 G50 G25 B100 B75 B50 B25 © 2013, Alexion Pharmaceuticals, Inc. All rights reserved. 1013.1.4.0.075 10/31/13 12:58 PM T: 14"

Table of Contents for the Digital Edition of ASH News Daily 2013 - Day 2

Table of Contents

ASH News Daily 2013 - Day 2

https://www.nxtbookmedia.com